AstraZeneca's Covid-19 vaccine not ready for quick EU nod: Regulator

Pakistan, Japan find cases with new coronavirus variants on their own soil

AstraZeneca
European regulators have only received some information about the vaccine
Agencies
2 min read Last Updated : Dec 30 2020 | 1:53 AM IST
The European Medicines Authority (EMA) will most likely not be able to approve the Covid-19 vaccine developed by drug maker AstraZeneca and the University of Oxford in January, the watchdog's Deputy Executive Director Noel Wathion said.
 
"They have not even filed an application with us yet", Wathion said in an interview with Belgian newspaper Het Nieuwsblad published on Tuesday.
 
European regulators have only received some information about the vaccine, Wathion said.
 
“Not even enough to warrant a conditional marketing licence”, he said. “We need additional data about the quality of the vaccine. And after that, the company has to formally apply.”  This made it “improbable” that an approval could already be granted next month, Wathion said.
 
UK virus variant detected in Pakistan
 
Pakistan on Tuesday confirmed its first case of the new coronavirus variant found in the UK after it identified the strain that spreads at a much faster pace in three samples taken from passengers who had returned from Britain.
 
The health department in Sindh said the samples of 12 returnees were taken for genotyping, out of which six tested positive.


 
"Samples of 3 UK returnees show a 95 per cent match to the new coronavirus variant from the UK in the first phase of genotyping," it said in a tweet.
 
South Africa variant found in Japan
 
Japan on Monday detected a coronavirus variant found in South Africa, the government said, the first such discovery in a nation that has already identified more than a dozen cases of another variant that is spreading rapidly in Britain.
 
Iran begins first human trial of locally made vaccine
 
The first study of the safety and effectiveness of a coronavirus vaccine in Iran began Tuesday, state TV reported, with dozens due to receive the domestically developed shot even as details about its production remained slim.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Coronavirus VaccineAstraZenecaEuropean Union

Next Story